American Journal of Kidney Diseases
Volume 55, Issue 5 , Pages 800-812 , May 2010

Canadian Society of Nephrology Commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD–Mineral and Bone Disorder (CKD-MBD)

  • Braden J. Manns, MD, MSc

      Affiliations

    • Foothills Medical Centre, Calgary, Alberta, Canada
    • Corresponding Author InformationAddress correspondence to Braden J. Manns, MD, MSc, Foothills Medical Centre, 1403–29th St NW, Calgary, Alberta, Canada T2N 2T9
    • ,
  • Anthony Hodsman, MB, FRCPC

      Affiliations

    • Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, Ontario, Canada
    • ,
  • Deborah L. Zimmerman, MD, MSc

      Affiliations

    • Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, Ottawa Hospital, Canada
    • ,
  • David C. Mendelssohn, MD, FRCPC

      Affiliations

    • Humber River Regional Hospital, University of Toronto, Canada
    • ,
  • Steven D. Soroka, BMus, MD, MSc, FRCPC, CHE

      Affiliations

    • Dalhousie University, Canada
    • Capital Health Hemodialysis, PreDialysis Program, and Nephrology Clinical Trials, Canada
    • Nova Scotia Provincial Dialysis Program, Canada
    • ,
  • Chris Chan, MD, FRCPC

      Affiliations

    • Home Hemodialysis, Toronto General Hospital/University Health Network, University of Toronto, Canada
    • ,
  • Kailash Jindal, MD, FRCPC

      Affiliations

    • University of Alberta, Edmonton, Alberta, Canada
    • ,
  • Scott Klarenbach, MD, MSc, FRCPC

      Affiliations

    • University of Alberta, Edmonton, Alberta, Canada

References 

  1. Manns BJ, White CT, Madore F, et al. Introduction to the Canadian Society of Nephrology clinical practice guidelines for the management of anemia associated with chronic kidney disease. Kidney Int Suppl. 2008;110:S1–S3
  2. National Kidney Foundation. IV. K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis. 2001;37(1 suppl 1):S182–S238
  3. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47(suppl 3):S1–S146
  4. McMahon L. The CARI guidelines (Biochemical and haematological targets. Haemoglobin). Nephrology (Carlton). 2008;13(suppl 2):S44–S56
  5. Locatelli F, Aljama P, Barany P, et al. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(suppl 2):ii1–ii47
  6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1–S130
  7. Rocco MV, Berns JS. KDOQI in the era of global guidelines. Am J Kidney Dis. 2009;54(5):781–787
  8. Jindal K, Chan CT, Deziel C, et al. Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol. 2006;17(3 suppl 1):S1–S27
  9. Levin A, Hemmelgarn B, Culleton B, et al. Guidelines for the management of chronic kidney disease. CMAJ. 2008;179(11):1154–1162
  10. Manns BJ, Mendelssohn DC, Taub KJ. The economics of end-stage renal disease care in Canada: incentives and impact on delivery of care. Int J Health Care Finance Econ. 2007;7(2-3):149–169
  11. Klarenbach SW. Economic evaluation in renal disease. J Nephrol. 2007;20(3):251–259
  12. Klarenbach S, Manns B. Economic evaluation of dialysis therapies. Semin Nephrol. 2009;29(5):524–532
  13. Mendelssohn DC. The evolution of nephrology guidelines: calling for a mid-course adjustment. Nephrol News Issues. 2009;23(9):41–44
  14. Phillips N, Barrett B, Mendelssohn DC. The role of physicians in political advocacy (Results of a Canadian Society of Nephrology survey). Nephrol News Issues. 2008;22(13):6–732-33
  15. Strippoli GF, Craig JC, Schena FP. The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol. 2004;15(2):411–419
  16. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31–38
  17. Hemmelgarn BR, Manns BJ, Zhang J, et al. Association between multidisciplinary care and survival for elderly patients with chronic kidney disease. J Am Soc Nephrol. 2007;18(3):993–999
  18. Hemmelgarn B, Manns B, Lloyd A, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010;303:423–429
  19. Brown JP, Josse RG. 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada. CMAJ. 2002;167(10 suppl):S1–S34
  20. Kanis JA WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporosis Int. 1994;4:368–381
  21. Siminoski KG, Leslie WD, Frame H. Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J. 2007;56:178–188
  22. Toussaint N, Cooney P, Kerr PG. Review of dialysate calcium concentration in hemodialysis. Hemodial Int. 2006;10(4):326–337
  23. Al-Hejaili F, Kortas C, Leitch R, et al. Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration. J Am Soc Nephrol. 2003;14(9):2322–2328
  24. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342(20):1478–1483
  25. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72(9):1130–1137
  26. Tonelli M, Wiebe N, Culleton B, et al. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant. 2007;22(10):2856–2866
  27. Jamal SA, Fitchett D, Lok CE, Mendelssohn DC, Tsuyuki RT. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. Nephrol Dial Transplant. 2009;24(10):3168–3174
  28. Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis. 2009;54(4):619–637
  29. St. Peter WL, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis. 2008;51(3):445–454
  30. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68(4):1815–1824
  31. Finn WF. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol. 2006;65(3):191–202
  32. Pfeffer MA, Burdmann EA, Chen CY, et al. TREAT Investigators A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019–2032
  33. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis. 2003;42(4 suppl 3):S1–S201
  34. Kestenbaum B, Andress DL, Schwartz SM, et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int. 2004;66(5):2010–2016

PII: S0272-6386(10)00487-7

doi: 10.1053/j.ajkd.2010.02.339

American Journal of Kidney Diseases
Volume 55, Issue 5 , Pages 800-812 , May 2010

Article Tools